Illumina, Inc. $ILMN Stake Cut by Andra AP fonden

Andra AP fonden cut its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 146,800 shares of the life sciences company’s stock after selling 13,900 shares during the period. Andra AP fonden’s holdings in Illumina were worth $19,254,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in ILMN. Capital World Investors lifted its stake in Illumina by 20.0% during the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares during the last quarter. Nordea Investment Management AB lifted its stake in Illumina by 2,792.2% in the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after buying an additional 911,843 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new stake in Illumina in the fourth quarter valued at $73,532,000. Norges Bank bought a new stake in Illumina in the fourth quarter valued at $70,844,000. Finally, State Street Corp lifted its stake in Illumina by 6.8% in the third quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock valued at $569,800,000 after buying an additional 382,520 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on ILMN. Barclays raised their target price on Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research note on Friday, May 1st. Canaccord Genuity Group cut their price objective on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. Evercore restated an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Guggenheim lifted their price objective on shares of Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a research note on Monday, June 1st. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Illumina has an average rating of “Hold” and a consensus price target of $142.13.

Insider Transactions at Illumina

In related news, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $98,400.00. Following the completion of the transaction, the insider directly owned 21,568 shares in the company, valued at $3,450,880. This represents a 2.77% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,154 shares of company stock worth $155,600,208 in the last three months. Insiders own 2.90% of the company’s stock.

Illumina Price Performance

NASDAQ:ILMN opened at $166.21 on Friday. The business’s 50-day moving average price is $140.96 and its 200 day moving average price is $134.80. The firm has a market cap of $25.15 billion, a P/E ratio of 30.22, a PEG ratio of 3.05 and a beta of 1.50. Illumina, Inc. has a 52-week low of $85.77 and a 52-week high of $177.22. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.Illumina’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the business posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.